Suzhou Fushilai Pharmaceutical Co. Ltd.
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and … Read more
Suzhou Fushilai Pharmaceutical Co. Ltd. - Asset Resilience Ratio
Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has an Asset Resilience Ratio of 45.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Suzhou Fushilai Pharmaceutical Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Suzhou Fushilai Pharmaceutical Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥977.61 Million | 45.84% |
| Total Liquid Assets | CN¥977.61 Million | 45.84% |
Asset Resilience Insights
- Very High Liquidity: Suzhou Fushilai Pharmaceutical Co. Ltd. maintains exceptional liquid asset reserves at 45.84% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Suzhou Fushilai Pharmaceutical Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Suzhou Fushilai Pharmaceutical Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Suzhou Fushilai Pharmaceutical Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 53.80% | CN¥1.12 Billion | CN¥2.09 Billion | +3.25pp |
| 2023-12-31 | 50.54% | CN¥1.07 Billion | CN¥2.12 Billion | -4.78pp |
| 2022-12-31 | 55.33% | CN¥1.16 Billion | CN¥2.10 Billion | +53.10pp |
| 2021-12-31 | 2.23% | CN¥21.61 Million | CN¥970.31 Million | -13.00pp |
| 2020-12-31 | 15.22% | CN¥120.00 Million | CN¥788.25 Million | +12.42pp |
| 2019-12-31 | 2.81% | CN¥21.10 Million | CN¥751.44 Million | -- |